Registration, Evaluation, Authorisation and Restriction of Chemicals

Bio-Process Systems Alliance Responds to European Chemicals Agency's Proposed Universal Ban on PFAS

Retrieved on: 
Jeudi, septembre 28, 2023
Bio Process Systems Alliance, Vaccine, PVDF, European Union Observatory for Nanomaterials, American Chemistry Council, BPSA, Organization, PFAS, Economy, ECHA, Polymer, United States of Europe, Organisation for Economic Co-operation and Development controversy, Multimedia, Mechanical, Development, Patient, PTFE, Risk, European Federation of Pharmaceutical Industries and Associations, REACH, Registration, Evaluation, Authorisation and Restriction of Chemicals, Health, Per- and polyfluoroalkyl substances, Environment, Society, Pharmaceutical industry, Fine chemical

PFAS are used extensively across multiple industries, including bioprocessing, due to their unique functional properties and low reactivity.

Key Points: 
  • PFAS are used extensively across multiple industries, including bioprocessing, due to their unique functional properties and low reactivity.
  • This restriction proposes a universal ban over time on the use of all fluoropolymers in all applications, without distinguishing between fluoropolymers and other PFAS substances.
  • "Let's find solutions that better balance the environmental and health concerns with the needs of patients, consumers and the bioprocessing industry."
  • We urge ECHA to reconsider its proposed restriction based on the available scientific data and risk assessments regarding PFAS substances, including fluoropolymers, used in bioprocessing.

Registration Now Open for "Preparing a PFAS Game Plan in the U.S., the UK, and the EU" Webinar

Retrieved on: 
Jeudi, juin 29, 2023
International Bar Association, PFAS, Policy, PSS, Risk assessment, American Bar Association, EPA, European Parliament Committee on the Environment, Public Health and Food Safety, Commerce, IBA, Natural Resources, REACH, TSCA, Registration, Evaluation, Authorisation and Restriction of Chemicals, Cosmetics, EU, Acta, Chemistry

WASHINGTON, June 29, 2023 /PRNewswire-PRWeb/ -- Registration is open now for "Preparing a PFAS Game Plan in the U.S., the UK, and the EU."

Key Points: 
  • WASHINGTON, June 29, 2023 /PRNewswire-PRWeb/ -- Registration is open now for "Preparing a PFAS Game Plan in the U.S., the UK, and the EU."
  • Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are attracting global legal, regulatory, commercial, and litigation attention as no other "emerging contaminant" has.
  • In the United States and globally, the number of bans, restrictions, and reporting requirements for PFAS increases seemingly daily.
  • The Acta Group (Acta®) and EPPA are pleased to offer this one-hour complimentary webinar providing companies with the information needed to develop a PFAS game plan.

Registration Now Open for "Preparing a PFAS Game Plan in the U.S., the UK, and the EU" Webinar

Retrieved on: 
Vendredi, juin 16, 2023
International Bar Association, PFAS, Policy, PSS, Risk assessment, American Bar Association, EPA, European Parliament Committee on the Environment, Public Health and Food Safety, IBA, Natural Resources, REACH, TSCA, Registration, Evaluation, Authorisation and Restriction of Chemicals, Commerce, Cosmetics, EU, Acta, Chemistry

WASHINGTON, June 16, 2023 /PRNewswire-PRWeb/ -- Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are attracting global legal, regulatory, commercial, and litigation attention as no other "emerging contaminant" has. Companies producing, processing, distributing, and/or using these substances must be aware of these global legal developments and take steps now to minimize legal, regulatory, and commercial risk.

Key Points: 
  • In the United States and globally, the number of bans, restrictions, and reporting requirements for PFAS increases seemingly daily.
  • The European Union (EU) is currently considering a proposal to restrict more than 10,000 PFAS under the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation.
  • This would be the most extensive regulatory restriction on PFAS to date, in one of the world's largest markets.
  • The Acta Group (Acta®) and EPPA are pleased to offer this one-hour complimentary webinar providing companies with the information needed to develop a PFAS game plan.

Confluent Medical Technologies Announces REACH and EU MDR Compliant Polyimide Tubing

Retrieved on: 
Lundi, juin 12, 2023
REACH, Registration, Evaluation, Authorisation and Restriction of Chemicals, MDR, Solvent, Confluence, Medical device, EU

CHATTANOOGA, Tenn., June 12, 2023 (GLOBE NEWSWIRE) -- Confluent Medical Technologies (Confluent), a leading medical device and materials science contract manufacturer specializing in high-precision polymer tubing, today announced the offering of REACH and EU Medical Device Regulation (MDR) Compliant Polyimide Tubing.

Key Points: 
  • CHATTANOOGA, Tenn., June 12, 2023 (GLOBE NEWSWIRE) -- Confluent Medical Technologies (Confluent), a leading medical device and materials science contract manufacturer specializing in high-precision polymer tubing, today announced the offering of REACH and EU Medical Device Regulation (MDR) Compliant Polyimide Tubing.
  • The industry standard polyimide, a material used extensively in medical applications such as vascular catheters, contains one of the restricted solvents.
  • “Confluent’s REACH Compliant Polyimide is made with no restricted substances, therefore, there are no restricted solvents to remove and no extensive and expensive testing is required.”
    Confluent’s REACH Compliant Polyimide uses industry standard chemistry resulting in product that looks and performs like traditional polyimide while avoiding the historical hurdles of ensuring EU compliance.
  • Confluent is offering their REACH Compliant Polyimide immediately with lead times of 4 weeks or less.

Quectel Certification Services offering speeds up time to market and takes away certification cost and complexities for IoT devices

Retrieved on: 
Mardi, mars 14, 2023
Technology, Mobile, Wireless, Telecommunications, IOT (Internet of Things), T-Mobile, Atmosphere, AT&T, Restriction of Hazardous Substances Directive, Overseas Marine Certification Services, Knowledge, WEEE, CE, GxP, ANATEL, Certification, Internet of things, TELUS, REACH, Multimedia, Registration, Evaluation, Authorisation and Restriction of Chemicals, IC, Verizon Communications, University, KC, AT, ATEX, FCC, RCM, Medical device, Vodafone

This service will enable customers’ devices to gain certifications in under eight weeks and is not only the fastest time to market for IoT device manufacturers, but also the industry’s most cost-effective offering.

Key Points: 
  • This service will enable customers’ devices to gain certifications in under eight weeks and is not only the fastest time to market for IoT device manufacturers, but also the industry’s most cost-effective offering.
  • View the full release here: https://www.businesswire.com/news/home/20230314005140/en/
    Quectel Certification Services offering speeds up time to market and takes away certification cost and complexities for IoT devices (Photo: Business Wire)
    Certification across these disciplines is complex to achieve, involves multiple layers of certification from disparate organisations and, typically, local and regional authorities award certifications for device deployments in their own territories.
  • “Going directly to certification or carrier organizations can result in it taking up to six months for IoT devices to gain certifications,” said Yoon Seungryoul, North American Certification Director, Quectel Wireless Solutions.
  • “We’re proud to have launched Quectel Certification Services and we’re ready to provide full, global certification consultation and service to integrated device customers that have products that are based on Quectel modules,” added Seungryoul.

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

Retrieved on: 
Mercredi, décembre 21, 2022
Registration, Evaluation, Authorisation and Restriction of Chemicals, Sumathi Best Television Current Reporting Award, Webcast, Commercial, The Scientist (magazine), Health, Research, LLP, G&A, Acceleration, Marketing, Risk, R&D, CELL, Cell, Cell biology, Communication, Proteome, Multimedia, Sale, Organization, Intellectual property, Conference, Failure, Prospectus, JOINT, Customer base, HIV disease progression rates, Workflow, Oil, Security (finance), Management, Retail, Fine chemical, Video game console, Bank, Pharmaceutical industry, Fierce, Isoplexis, Shareholder

EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (Nasdaq: BLI), a life sciences tools company, and IsoPlexis (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.

Key Points: 
  • The combined company, which will be named PhenomeX (Nasdaq: CELL), will be a premier functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
  • As the combination of Berkeley Lights and IsoPlexis, PhenomeX's mission is to empower researchers to leverage the full potential of functional cell biology and shape the next wave of scientific revolution.
  • The combined company will unite complementary portfolios that will extend its leadership through the functional cell biology continuum with highly differentiated technology.
  • In connection with the proposed transaction between Berkeley Lights and IsoPlexis, Berkeley Lights and IsoPlexis intend to file relevant materials with the SEC, including a Berkeley Lights registration statement on Form S‑4 that will include a joint proxy statement of Berkeley Lights and IsoPlexis that also constitutes a prospectus of Berkeley Lights.

Applied Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Mercredi, novembre 9, 2022
Quality of life, GLOBE, Private Securities Litigation Reform Act, Fibrosis, Forward-looking statement, Prevalence, Investment, Doctor of Philosophy, Patent, Safety, Research, Intention, Eye, Board, Diagnosis, Disease, Mortality, PMM2-CDG, Therapy, Hospital, Registration, Evaluation, Authorisation and Restriction of Chemicals, NASDAQ, Patient, U.S. Securities and Exchange Commission, Diabetic cardiomyopathy, EMA, Company, Government, ARI, Clinical trial, Diabetic retinopathy, Heart, CEO, Review, MAA, DMC, American Heart Association, Central nervous system, Industry, Insurance, CNS, COVID-19, Pharmaceutical industry, Cryptocurrency

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the Company), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the Company), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022.
  • In the third quarter, we made significant progress across all three of our late-stage programs, said Shoshana Shendelman, PhD, Founder, CEO and Chair of the Board of Applied Therapeutics.
  • In October 2022, the Company announced full enrollment in the Phase 3 registrational ARISE-HF trial studying AT-001 in patients with DbCM.
  • Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.

Y-Warm Exhibits the Latest Product with Its Cooperating Partners in CIFTIS 2022

Retrieved on: 
Mercredi, août 31, 2022
Research, SVHC, Underweight, Porosity, Registration, Evaluation, Authorisation and Restriction of Chemicals, Permeability, China National Convention Center, International Fair, Industry

Beijing, China--(Newsfile Corp. - August 31, 2022) - China International Fair for Trade in Services (CIFTIS) will be held in China National Convention Center, Beijing on August 31st, 2022.

Key Points: 
  • Beijing, China--(Newsfile Corp. - August 31, 2022) - China International Fair for Trade in Services (CIFTIS) will be held in China National Convention Center, Beijing on August 31st, 2022.
  • It is the only international and comprehensive platform for the service trade, which is organized by Beijing Capital Group Exhibitions & Events.
  • Y-Warm exhibited the latest application of its high-performance insulation material with the cooperation partners.
  • Y-Warm and its cooperating partner exhibited the application and released the latest research results in CIFTIS 2022.

M. Holland Company Announces REACH Compliance from ECHA

Retrieved on: 
Lundi, juillet 25, 2022
Packaging, Chemicals, Plastics, Other Manufacturing, Manufacturing, Original equipment manufacturer, LLDPE, Registration, Evaluation, Authorisation and Restriction of Chemicals, Twitter, ECHA, European Chemicals Agency, Culture, Compliance, Health, Risk management, REACH, HDPE, Certification, Plastic, LinkedIn, LDPE, Fine chemical, EU, Facebook, European

Today M. Holland Company, a leading international distributor of thermoplastic resins and ancillary materials , announced that it has obtained Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) compliance for its proprietary Mtegrity line of materials.

Key Points: 
  • Today M. Holland Company, a leading international distributor of thermoplastic resins and ancillary materials , announced that it has obtained Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) compliance for its proprietary Mtegrity line of materials.
  • This level of certification positions M. Holland as a strategic business partner for European OEMs and plastics manufacturers.
  • Europe continues to expand its sustainable initiatives in the plastics industry, leading the way for other regions, said Jen Riley-Brady, vice president, international for M. Holland Company.
  • For more information on M. Hollands international business offerings and REACH compliance, visit www.mholland.com/our-businesses/international .

Water Blocking Tapes Market Report 2022-2027: Growth in Cross-Continental Power and Data Cables Driving Industry - ResearchAndMarkets.com

Retrieved on: 
Mardi, juillet 5, 2022
Engineering, Other Manufacturing, Manufacturing, Water, REACH, USD, Row, United States Environmental Protection Agency, Optics, Growth, Union, Globally Harmonized System of Classification and Labelling of Chemicals, EPA, Control, Substance, CAGR, Technology, Control of Substances Hazardous to Health Regulations 2002, Electrical conductor, Registration, Evaluation, Authorisation and Restriction of Chemicals, COSHH, Globe, Chemical industry, GHS, Renewable energy, EU

The increasing demand for water blocking tapes in power and telecommunication projects is one of the most significant factors projected to drive the growth of the water blocking tapes market.

Key Points: 
  • The increasing demand for water blocking tapes in power and telecommunication projects is one of the most significant factors projected to drive the growth of the water blocking tapes market.
  • The water-blocking tapes market is segmented into three different types, namely, conductive, semi-conductive, and non-conductive tapes.
  • The non-conductive water-blocking tapes absorb liquid quickly at the point of insulation failure and swell swiftly to prevent further penetration.
  • The US accounted for the largest share in terms of value and volume, of the water blocking tapes market in 2021.